BET, SRC, AND BCL2 FAMILY INHIBITORS ARE SYNERGISTIC DRUG COMBINATIONS WITH PARP INHIBITORS IN OVARIAN CANCER

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer

Background: Homologous Tea recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a preferred treatment option.However, a considerable proportion of these carcinomas acquire resistance or harbour de novo resistance, posing a significant challenge to treatment.

read more